Refining the Maintenance Protocol for Advanced Ovarian Cancer

Target Audience

The intended audience for this activity are gynecologic oncologists, medical oncologists, OB/GYNs, NPs, PAs, pharmacists, and other health care professionals involved in the care of patients with ovarian cancer.

Statement of Need/Program Overview

The recent availability of PARP inhibitors as maintenance therapy in the first-line setting allows clinicians to offer improved treatment options to their patients with ovarian cancer. Join experts in the field as they examine the rationale for PARP inhibitors, the role of homologous recombination deficiency (HRD), as well as the efficacy and safety data that led to recent approvals for maintenance therapy. Case-based learning will exemplify the application of recent clinical-trial findings to treatment and patient selection, as well as side-effect management. Snapshots of patient preferences and strategies to improve communication with patients and other caregivers will be discussed to ensure care is optimized for every patient.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Review currently approved maintenance therapy and evidence-based guidelines
Evaluate the role of PARP inhibitors and their efficacy in clinical subgroups
Assess the current and emerging PARP inhibitors for maintenance therapy, including efficacy data and novel dosing schedules
Interpret protocols to effectively manage adverse events, individualize dosing schedules, and improve patient outcomes
Appraise clinical data for selection of first-line maintenance treatment for patients with varying clinical profiles